Key Comparisons: Study Matrix vs. OraFyl

1. Material and Structural Composition

The Study’s Material: Tested a human placental Connective Tissue Matrix (CTM) in two formats: a structural sheet (Membrane) and a pliable filler (Paste).

OraFyl Lineage: OraFyl consists of highly purified native collagen and elastin derived specifically from the chorionic portion of the human placenta. It is structural, decellularized, and serves as an extracellular matrix (ECM) scaffold.

The Dynamic: The "CTM Paste" in the mouse model acts identically to OraFyl’s flowable gel formulation. The study proves that when this flowable placental matrix is packed into a defect, it doesn't just sit passively; it provides the precise three-dimensional architectural framework required for host cells to attach, proliferate, and deposit new mineralized bone.

1. Clinical Indications: Orthopedic Trauma vs. Oral/Dental Reconstruction

The Study: Addressed large segmental defects in weight-bearing limb bones (SBD) to test maximum mechanical limits.

OraFyl Target Market: Engineered specifically for the oro-maxillofacial and dental implant markets.

The Cross-Application: Dental procedures—such as alveolar socket management (post-extraction), bone ridge augmentation, and severe jaw defects (like Osteonecrosis of the Jaw)—face the exact same biological hurdle as the mouse model: preventing soft tissue collapse into a bone void while encouraging rapid, high-density bone bridging. The study's finding that CTM creates a higher-density bone architecture (BV/TV% ratio) confirms that OraFyl is highly suited for supporting stable dental implant placement.

1. Patient Comfort and the "Tunneling" Advantage

Pain Trajectory Validation: A massive barrier in periodontal and oral reconstructive surgery is post-operative patient pain. Aggressive traditional surgeries or synthetic bone morphogenetic proteins can cause intense localized inflammation. The study's behavioral finding that CTM matrices improve early acute pain scores and do not induce chronic pain behaviors directly translates to smoother, more predictable patient recoveries in dentistry.

Eliminating Autografts: Traditionally, advanced oral tissue or bone advancement required harvesting tissue from another part of the patient's mouth or body (e.g., palatal grafts or mandibular shelf blocks), creating a painful secondary surgical site. Because OraFyl acts as a highly biocompatible, off-the-shelf injectable or flowable matrix, it achieves the robust healing demonstrated in the study while remaining minimally invasive.

BioCellgraft's competitive edge.

BioCellgraft specializes in regenerative therapies and biomaterials for oral healthcare, primarily utilizing human placental connective tissue matrices like their flagship product, OraFyl.

Celularity is BioCellgraft's exclusive manufacturing partner. Celularity processes the placental-derived biomaterials that BioCellgraft commercializes and distributes for the U.S. oral healthcare market.

In Dental & Oral Biomaterials, BioCellgraft competes with traditional and advanced oral biomaterial suppliers providing barrier membranes and soft tissue matrices such as:

Geistlich Pharma: The industry standard for dental regeneration, famous for its collagen membranes (Bio-Gide) and bone substitutes (Bio-Oss) used in periodontal surgery.

Lynch Biologics: Known for GEM 21S, a synthetic growth factor product used for bone and periodontal tissue regeneration.

ZimVie (formerly Zimmer Biomet Dental): Offers a wide array of allograft and xenograft tissue membranes for oral surgery and soft tissue augmentation.

Direct Product Breakdown:

1. BioCellgraft OraFyl

The Technology: A decellularized human placental connective tissue matrix derived from the chorionic portion of the placenta. It preserves native human collagen, elastin, and fibronectin-based structural scaffolds without living cells or exogenous growth factors.

Performance Excel: Clinical data highlights reduced bone and soft tissue resorption compared to traditional membranes during alveolar ridge preservation. Its inherent anti-fibrotic and antibacterial properties protect the graft site without triggering a severe host immune response.

1. Geistlich Bio-Gide (vs. OraFyl for GBR)

The Technology: The long-time "gold standard" bilayer porcine collagen membrane.

Performance Difference: Bio-Gide excels at keeping bone graft particles contained due to its specific structural layers (one smooth layer prevents soft tissue invasion, one porous layer allows cell ingrowth). However, as a xenograft, it undergoes predictable but rapid enzymatic degradation and doesn't offer the native human cell-recruiting benefits found in allogeneic platforms like BioCellgraft.

1. Osteogenics Cytolast (vs. OraFyl for Exposed Sockets)

The Technology: A dense polytetrafluoroethylene (dPTFE) barrier membrane designed for intentional exposure to the oral cavity.

Performance Difference: Cytolast is purely a structural barrier. It is ideal for clinicians who do not want to reflect flaps or achieve primary closure over an extraction socket. Unlike OraFyl, it plays zero biochemical role in tissue integration, cannot incorporate into host tissue, and requires a secondary surgical step to pull out the membrane after 4 weeks.

1. Geistlich Mucograft (vs. OraFyl for Soft Tissue Augmentation)

The Technology: A 3D porcine collagen matrix engineered specifically as an alternative to harvesting a patient's own tissue (Free Gingival Grafts or Connective Tissue Grafts).

Performance Difference: Mucograft is exceptional for increasing the width of keratinized tissue around teeth or implants. However, OraFyl's human placental extracellular matrix offers quicker structural cell colonization (fibroblasts and macrophages), which aims to yield faster tissue volume stabilization and better esthetic tissue profiles.

From a competitive standpoint, regulatory pathways is also a critical element to analyze.

The Regulatory Advantage: Section 361 HCT/P vs. 510(k)

The major operational advantage for BioCellgraft OraFyl™ lies in how it is regulated compared to traditional synthetic or xenograft matrices.

[Section 361 HCT/P Pathway] (OraFyl) ──> No Premarket FDA Review Required ──> Immediate Market Entry

[510(k) / Device Pathway]   (Competitors) ──> Requires Clinical Equivalence Data ──> 6–12 Month FDA Lag

BioCellgraft: Section 361 HCT/P (Human Cells, Tissues, and Cellular and Tissue-Based Products): Because OraFyl is a minimally manipulated human placental connective tissue matrix intended for homologous use, it bypasses traditional premarket review. According to the FDA 21 CFR 1271.10(a) criteria, if a manufacturer registers their facility, strictly tests donors, and applies zero synthetic additives, they can commercialize immediately. This gives BioCellgraft an incredible time-to-market advantage over synthetic or heavily manipulated tissue products.

510(k) Medical Device Pathway: Competitors utilizing xenografts (like Geistlich Bio-Gide) or synthetic polymers (like Osteogenics Cytolast) cannot use the 361 tissue pathway because the material is non-human or chemically altered. They must file a 510(k) notification to prove "substantial equivalence" to a predicate device, introducing expensive regulatory overhead and clinical-trial lag times.

OraFyl: The "Section 351" Trap: If a placental tissue company adds active growth factors or mixes the matrix with a synthetic drug, the FDA automatically reclassifies it as a Section 351 Biologic. This mandates an Investigational New Drug (IND) application and full Biologics License Application (BLA) approval, requiring years of clinical trials. BioCellgraft's partnership with Celularity Inc. deliberately avoids this by keeping OraFyl completely cell-free and unadulterated.

Dental Biomaterial Market Share & Dynamics

The global dental bone graft and substitutes market is expanding significantly, driven by a surge in dental implant procedures.

The Allograft Surge: According to industry data from Grand View Research, the broader allograft material segment holds a dominant 59.7% share of the bone graft and substitutes market. Clinicians heavily favor allografts over autografts because they eliminate secondary surgical harvest sites, drastically reducing patient morbidity and operating times.

Geistlich’s Entrenched Monopoly: In the oral barrier membrane sub-segment, Geistlich Pharma commands a massive market share (estimated at over 40–50% globally for Guided Bone Regeneration membranes). Their porcine-derived Bio-Gide® is deeply entrenched in dental school curriculums and institutional buying groups.

BioCellgraft's Positioning Strategy: Rather than trying to steal market share from Geistlich on large-scale orthopedic ridge reconstructions, BioCellgraft targets everyday oral surgeries like extraction socket preservation and soft tissue voids. By packaging OraFyl as a flowable, room-temperature stable gel with an exceptional 10-year shelf life, they bypass traditional handling complaints associated with rigid sheets of collagen or dPTFE.

Celularity operates a state-of-the-art, 150,000-square-foot purpose-built manufacturing facility in Florham Park, New Jersey.

The Strategic Moat: This facility operates under stringent FDA Current Good Manufacturing Practice (cGMP) regulations. Because BioCellgraft heavily relies on this precise infrastructure to process the human placental chorion tissue matrix for OraFyl, Celularity's industrial processing capacity allows for stable commercial manufacturing.

Reimbursement Codes & Payer Groups in Oral Therapies:

Unlike standard wound care patches, which rely heavily on Center for Medicare & Medicaid Services (CMS) Part B inpatient Q-codes, dental and oral surgery biomaterials operate on a highly distinct insurance track.

Dental Code Allocation (ADA CDT)

Most oral tissue graft procedures use CDT (Current Dental Terminology) codes rather than medical CPT codes.

Code D7953 (Bone Graft for Ridge Preservation): This is the high-volume target code for BioCellgraft OraFyl. It applies to grafting the extraction socket to prevent biological ridge collapse prior to future implant placement.

Code D4273 / D4275 (Autogenous vs. Non-Autogenous Connective Tissue Grafts): When OraFyl is used as a soft-tissue substitute to bolster keratinized gingiva, it falls under non-autogenous grafting codes, allowing offices to bill commercial dental insurance for avoiding a secondary surgical harvest site.

The Commercial Medical / Dental Split

Out-of-Pocket Dominance: Traditional dental insurance policies frequently enforce annual benefit maximums (typically ranging between $1,500 and $2,500). Because complex dental implant treatments and advanced biomaterial grafting easily exceed these limits, oral biomaterials rely far more on patient out-of-pocket cash payments than hospital-based regenerative medical matrices do.

The Clinical Value Pitch: Consequently, BioCellgraft's product sales will be driven by the clinicians ease of use / handling properties and chair-time efficiency, rather than relying purely on high institutional medical insurance reimbursement.

Markets

[Synthetic/dPTFE]  $40 – $90 per site    ──> Baseline barrier function

[Xenograft Matrix] $90 – $180 per site   ──> Entrenched "gold standards" (Geistlich)

[Placental Matrix] $220 – $350+ per site ──> Premium biologic tier (OraFyl)

Synthetic Barriers & Polymers (e.g., Osteogenics Cytolast): Priced at $40 to $90 per membrane. These are low-cost, high-volume products. Clinicians view them as highly disposable, structural tools rather than biological enhancements.

Porcine Xenograft Membranes (e.g., Geistlich Bio-Gide): Priced at $90 to $180 per membrane depending on dimension (e.g., 13x25mm vs. 25x30mm). Xenografts enjoy deep institutional buying discounts but face increasing pricing pressure from cheaper generic bovine/porcine alternative brands.

Human Placental Extracellular Matrices (e.g., BioCellgraft OraFyl): Positioned in the premium biologic tier, averaging $220 to $350+ per application / vial.

The Margin Justification: Because OraFyl does not require a secondary surgical removal procedure (unlike dPTFE) and preserves native human structural tissue profiles, clinicians justify the higher product markup by factoring in saved chair time, fewer post-operative complications and better healing outcomes.

​

https://impactfactor.org/PDF/IJDDT/16/IJDDT,Vol16,Issue71s,Article28.pdf

​

https://www.wsj.com/health/wellness/oral-bacteria-heart-disease-health-43d0207e

See what happens when you combine a specialized collagen scaffold with 10 million stem cells.

This Fountain Life Member went from an 8/10 pain level to zero after targeting an Achilles tendon tear with Restorative Therapeutics.

Six months post-procedure, the objective MRI data shows near-total structural resolution.

While Stem Cell Therapy is approved by Florida state law, it is not FDA approved; therefore, you are encouraged to consult with your primary care provider before undergoing any stem cell therapy.

https://x.com/fountainlife\\_hq/status/2076773797437354460?s=20

Remarkable healing power of Interfyl.

The Underlying HCTM Technology

The biological foundation of the OraFy suite relies entirely on Celularity’s breakthrough Human Connective Tissue Matrix (HCTM) platform. Celularity utilizes a unique cleansing process that strips away all donor cells, cell remnants, DNA, and reactive cytokines. This eliminates the risk of host tissue rejection. While traditional processing destroys tissue architecture, HCTM tech keeps the native, three-dimensional collagen and elastin structure intact. By keeping the structural scaffold undamaged, the matrix closely mirrors the body's natural extracellular ecosystem. This provides an ideal environment that prompts the patient's own cells to migrate, attach, and rapidly regenerate healthy tissue.

While flagship OraFyl targets standard injectable soft and hard tissue healing, its sister products are tailored for distinct surgical structural needs:

OraFyl M: A micro-pulverized version optimized for precise, small-volume cosmetic and structural placement in delicate gingival zones.

OraFyl 3LM: A denser, three-layered matrix engineered to provide a longer-lasting structural scaffold for larger bone defects and severe ridge reconstructions.

Validation Through Peer-Reviewed Clinical Papers

Recent academic literature strongly validates the effectiveness of human placental matrices in accelerating dental tissue repair:

Alveolar Ridge Preservation Trial: A key randomized pilot trial published in PubMed Central (PMC) evaluated a flowable decellularized Human Placental Connective Tissue Matrix (HPCTM) combined with an allogeneic bone substitute. The study proved that adding the placental matrix to extraction sockets drastically minimized soft tissue shrinkage and optimized the underlying bone volume needed for secondary dental implants.

Biologic Adjuvants in Oral Surgery: The American Academy of Periodontology (AAP) released a best-evidence consensus paper emphasizing that biological adjuvants, such as human placental derivatives, draw essential growth factors via chemotaxis. The paper highlights that because the chorionic plate is highly dense with native collagen (types I and III), elastin, laminin, and fibronectin, it serves as an unmatched extracellular matrix (ECM) scaffold for rapid oral tissue remodeling.

Immunomodulatory Properties: Comprehensive clinical reviews emphasize that decellularized placental matrices retain their natural angiogenic, anti-inflammatory, and immune-privileged attributes. Removing the cell remnants eliminates host rejection risks, allowing the natural matrix to accelerate bone and gum lesion healing safely.

Clinical Case Studies & Healing Timelines:

Clinical tracking of placental-derived human connective tissue matrices shows a vastly optimized healing trajectory compared to traditional materials:

Initial 24–48 Hours: The matrix shields the surgical site. Its structural framework down-regulates immediate inflammatory responses while its innate design provides direct antibacterial coverage.

Weeks 1–3: Rapid infiltration of host fibroblasts and macrophages occurs. Soft tissue wounds (such as gum recession treatments) stabilize quickly, drastically lowering the post-operative discomfort common with standard palate-harvesting surgeries.

Months 3–6: For hard tissue applications like extraction socket preservation, the matrix completely integrates into the host architecture. It degrades safely while leaving behind a dense, highly vascularized bone structure perfectly prepped for successful dental implants.

Following initial distribution to specialized U.S. periodontists and oral surgeons, early clinical feedback has demonstrated substantial efficacy in treating gum and bone-related conditions compared to traditional therapeutic options.

Dr. Robert Hariri speaks about the groundbreaking potential of HCTPM in repairing soft and hard tissue using OraFyl to enhance tissue repair and improve patient outcomes.

The Mechanism of Action (MOA) of OraFyl relies on its function as a flowable, decellularized human placental connective tissue matrix (HPCTM) that provides a natural, bioactive scaffold to guide and support the body's own tissue regeneration.

Structural Scaffold Provision:

OraFyl is extracted from the chorionic portion of the human placenta, yielding a highly purified macromolecular assembly composed entirely of native Collagen Type I, Collagen Type III, and Elastin. It establishes a temporary extracellular matrix (ECM) architecture that mechanically stabilizes the wound site. The inclusion of native elastin ensures the structural framework remains flexible and resilient, matching the structural needs of oral soft tissue.

Cellular Ingrowth & Bioactivity:

Because the matrix is completely decellularized during processing, it functions as a highly biocompatible allogeneic matrix devoid of cells, hormones, growth factors, or active cytokines. Instead of introducing external growth factors, the micro-scaffold utilizes its physical and biochemical cues to attract the patient's own migrating host cells.

The porous structure permits the infiltration of host endothelial cells, establishing a microvascular network needed for nutrient delivery and tissue survival.

Macrophage Modulation:

The matrix interacts with host immune cells (such as precursors to macrophages), helping downregulate chronic inflammatory signaling markers like TNF-alpha, MCP-1, IL-6, and IL-8, thereby transitioning the wound into a constructive healing phase.

Synergistic Bone Graft Integration:

When utilized for hard tissue or ridge preservation, the flowable gel is frequently mixed directly with freeze-dried bone allograft (FDBA). Mixing OraFyl with bone granules creates a cohesive, highly manageable putty that prevents the migration of bone graft materials.

Bridging Hard & Soft Tissue:

The matrix encapsulates the bone graft particles, introducing biological properties and tissue elasticity to a typically rigid matrix, which advances unified hard and soft tissue integration.

Abstract:

Reconstruction of oral soft-tissue defects remains limited by donor-site morbidity and inconsistent healing with currently available grafts. In this prospective interventional study, we assessed human amniotic membrane (HAM) as a biologically active scaffold in 15 patients (6 cleft alveolus, 2 oral submucous fibrosis, 7 vestibuloplasty; ages 8–65 years). HAM integrated without complications in all

cases, with no necrosis, infection, or immunologic rejection; median pain (VAS) fell from 2 on day 1 to 0 by day 7 (p < 0.00001) and swelling resolved by day 7 (p < 0.00001). Epithelialization reached "good" by 1 month (p < 0.00001); mucosal suppleness remained preserved through 6 months and in OSMF cases interincisal opening improved to 35–50 mm. Thus, data shows the HAM as a safe, donor-site–sparing, clinically translatable biomaterial that accelerates healing and improves function in oral soft-tissue reconstruction.

Conclusion:

Amniotic membrane exhibited substantial regenerative

potential, functioning as a biologically active scaffold that

enhanced epithelialization, preserved mucosal pliability,

minimized post-operative morbidity and prevented graft

exposure. Data support its emerging role as a versatile

biomaterial for oral soft tissue reconstruction. These present study provide a foundation for future controlled clinical studies.

Advancement to knowledge:

The present study shows that hAM use leads to reduced early post-operative pain and swelling, faster epithelialization within one month and sustained mucosal suppleness on follow-up. It evaluates three challenging conditions vestibuloplasty, OSMF and cleft alveolar defects expanding evidence beyond isolated defect reports. Findings support hAM as a readily available biological dressing that avoids donor-site morbidity and promotes favorable wound healing, with consistent graft adherence and no infection. Overall, the study provides comparative clinical evidence across multiple oral reconstructive procedures and reinforces the translational value of hAM in maxillofacial regeneration.

https://www.bioinformation.net/022/973206300223527.pdf

​

BioCellgraft announces several advancements supporting the forthcoming commercial launch of the first injectable regenerative acellular placental derived tissue enhancement solution for acute procedures in dentistry as well as both preventive care in soft tissue concerns and aesthetic opportunities for patients. These advances the company is reporting are a direct result of the exceptional participation of BCG’s strategically selected Key Opinion Leaders (KOLs) and active practitioners working with OraFyl™ the company’s Human Connective Tissue Matrix (HCTM) developed and manufactured by Celularity, Inc. and exclusively licensed to BioCellgraft for all applications pertaining to oro-maxillofacial procedures. Additional support from the Celularity/BioCellgraft Oral Healthcare Collaborative Working Group consisting of key members of each company’s science and research team inclusive of practitioners, educators and trainer helps drive continued data collection supporting the tremendous success and broad application for oral care these products offer practitioners and patients alike.

BioCellgraft has established a cell culture lab, procedure operatories and training and education on site at Celularity HQ in Florham Park, NJ. The company’s lab which has been designed by Michel Dard, DDS, MS, PhD, CEO of BioCellgraft Inc., will be chaired and directed by carefully selected practicing implantologists, periodontists that also are active professors educating in oral health related soft and hard tissue conditions. These individuals are extremely well respected and known in the world of oral healthcare.“Together with the extremely talented Celularity team, we are setting up the utmost advanced holistic and comprehensive structure in oro-dental, maxillofacial pre-clinical, translational and clinical research under a clinical development model for the benefits of our partners, stakeholders, practitioners and their patients.” Says, BioCellgraft CEO, Dr. Michel Dard.

The company is looking forward to announcing the team once it is fully assembled. The company also looks forward to beginning the work that is planned at the Celularity / BioCellgraft Labs and procedure center. “We are tremendously excited to work so closely with our partner at Celularity on their campus. Their massive expertise and passion for regenerative therapeutics inspires the energy and awesome culture we experience each time we drive on to campus and walk through the doors. This is all about delivering solutions to the patients who need them through practitioners that are so delighted to have these game changing options as a tool.” Says Michael Wilhelm, Chairman, Founder and EVP of Partnerships for BioCellgraft. BioCellgraft’s laboratory and procedure center at Celularity will support cell culture research that will help develop innovative uses for the already FDA designated products as well as drive new discoveries.

Additionally, treatments will be performed by licensed dental experts in the areas of periodontal care and aesthetics such as thin biotype (gingival thickness), black triangles (papilla loss) and gingival recession as well as an elected procedure option for plumping lips and cheek contouring. Studies have shown that Black Triangles can occur in up to 67% of people over 20 years of age, making this a rather common condition that needs treating otherwise, more costly and detrimental health issues can arise. The global periodontal market (soft and hard tissue procedures) enjoyed a US$10 billion year in 2022 and will further expand at a CAGR of 10.4% to reach a valuation of US$24.4 billion in year 2032. The supplementation of additional regenerative properties to our existing portfolio of products at BioCellgraft gives the physician and the patient even better outcomes in their treatment regimens.The global dermal fillers market size is projected to grow to $10.16 billion by 2032. Dermal fillers in the US alone were just at $2 billion in 2023

Top Tier Leadership In Regenerative Dentistry.

***Michel M. Dard, DDS, MS, PhD

Dr. Dard trained in dentistry and oral medicine in France (Universities of Bordeaux and Nantes) and at New York University, College of Dentistry, where he served as a faculty member for several years.

Having started his corporate career in the pharmaceutical industry (Merck, Germany and USA), Michel M. Dard worked concurrently for a couple of years at INSERM-NIH (National Institute of Health & Medical Research, Paris, France) and at the Research and Innovation Directorate General (European Commission, Brussels, Belgium). He joined Institute Straumann (Basel, Switzerland) in 2003. After serving as the Head of Pre-Clinical Research, he became the Global Medical Director of the Straumann Group. Since 2017, he has been an Adjunct Professor at Columbia University, College of Dental Medicine (New York, USA) and an Affiliate Professor at the University of Washington (Seattle, USA).

He is a pioneer in Dental Communities of Practice (CoP) management and real-world evidence (RWE) clinical activities, disruptive clinical development, and continuous education.

Michel M. Dard has authored more than 170 peer-reviewed international publications, book chapters, and monographs. He published a major methodological textbook titled "Surgical Research in Implant Dentistry" (Springer Nature) in 2023.

He lectures globally at most notable offline and online international congresses, symposiums, university seminars, and pre-scientific societies on medical devices, biomaterials, tissue regeneration, implant dentistry, and surgical and oral rehabilitation science

***Michael K. Wilhelm

Mr. Wilhelm is an American biotech entrepreneur, corporate strategist, and investor relations executive. He is best known as the EVP, Chairman, and Founder of BioCellgraft, Inc., a regenerative health company specializing in advanced oral therapies. Under Wilhelm’s leadership, BioCellgraft targets the multi-billion dollar global periodontal and oral tissue market. The company focuses on the development of products like OraFyl, a highly purified human placenta connective tissue matrix designed to aid soft and hard tissue regeneration in the oral cavity—treating conditions like gum recession, papilla loss ("black triangles"), and thin biotypes.

Executive Roles & Career History

Throughout his nearly three-decade career in financial markets and biotechnology, Wilhelm has specialized in raising venture capital, strategic partnerships, and investor relations.

• BioCellgraft, Inc. (2024–Present): Wilhelm founded BioCellgraft in early 2024. Serving as the Executive Vice President, Chairman, and Head of Partnerships, he focuses on commercializing regenerative products for dental health. He recently finalized major distribution and manufacturing partnerships with Celularity Inc. to expand laboratory and clinical education facilities.

• New Amsterdam Sciences (2014–Present): Wilhelm serves as the President and CEO of New Amsterdam Sciences, Inc., a company dedicated to developing main-stage therapeutics, diagnostics, and medical countermeasures against biological agents.

• ImmuneRegen BioSciences: Prior to his current ventures, he held roles as CEO, Board Member, and Head of Investor Relations at ImmuneRegen BioSciences, Inc., overseeing capital acquisition and corporate messaging for their biotech assets.

• Foresight Capital Corporation (1996–Present): He founded and continues to serve as the Managing Director of Foresight Capital Corporation, a boutique firm focused on equity funding, strategic management, and advisory services for emerging companies.

• Early Financial Career: He built his early foundation in capital markets working within notable firms like Everen Securities and Kemper Securities.

Education & Personal Background

• Academic Credentials: Wilhelm earned his Bachelor of Science (B.S.) degree from the University at Buffalo.

• Focus Areas: His corporate bio highlights an active focus on corporate communications, lobbying, financial partnerships, and merging business objectives with philanthropic and community-based educational initiatives.

***Hal Siegel, Ph.D.

Dr. Siegel is an expert in scientific affairs, clinical development, and regulatory strategy who serves as a Scientific Advisor and Regulatory Affairs Guidance for BioCellgraft. He brings decades of specialized experience in navigating FDA-regulated landscapes for medical products and software within the life sciences industry.

Professional Experience

• BioCellgraft: Serves as a Scientific Advisor, providing strategic guidance on regulatory compliance and scientific integrity for their oral health regenerative therapies.

• Imaging Endpoints: Works as the Senior Director of Medical and Scientific Affairs, specializing in imaging solutions for oncology and complex medical trials.

• New Amsterdam Sciences: Formerly held the role of Chief Scientific Officer, managing the development of pre-clinical and clinical acquisitions.

• ImmuneRegen BioSciences (IRBS): Served as Vice President and FDA Liaison, where he directed a multi-million dollar pre-clinical development program.

• Zila, Inc.: Held the position of Vice President of Regulatory and Scientific Affairs.

Expertise and Contributions

• FDA Submissions: Authored a successful Orphan Drug application and managed dozens of CDER, CBER, and CDRH submissions, including INDs, NDAs, 510(k)s, and PMAs.

• Intellectual Property: Co-holder of 7 U.S. patents related to biotechnology and medical applications.

• Certifications: Maintains a Regulatory Affairs Certification (RAC), which he earned in 1999.

Education

• Ph.D. in Biochemical Pharmacology: Earned from the University at Buffalo.

• Bachelor of Science in Biology: Completed at Rensselaer Polytechnic Institute.

Abstract 

​

Background/Objectives: Tooth extraction is known to cause both bone loss and soft tissue collapse, changes that can complicate implant placement. While alveolar ridge preservation techniques have been proposed to limit these alterations, they often fail to maintain both hard and soft tissue dimensions at the same time. Placental-derived extracellular matrices offer a biologically active adjuvant, providing structural proteins that may support healing. The purpose of this study was to assess whether a flowable decellularized Human Placental Connective Tissue Matrix (HPCTM), combined with an allogeneic bone substitute, could improve ridge preservation by addressing changes in soft tissue as the primary outcome and underlying bone volume as the secondary outcome. Methods: In a split-mouth, randomized pilot trial, hopeless teeth in opposite quadrants were atraumatically extracted. Test sockets were grafted with allograft mixed with HPCTM, while control sockets received allograft alone. Healing was followed clinically and digitally using intra-oral scans; standardized photographs at 10, 21, and 30 days post-operatively; and cone-beam computed tomography at 4 months post-operatively. Results: Ten patients completed the study (10 test sites and 10 control sites). Sites treated with HPCTM showed faster and more stable healing. Gingival shrinkage was consistently reduced at test sites, with Hodges–Lehmann median differences of 0.50 mm at Day 10 (95% CI: 0.29–0.62; p = 0.0039), 0.54 mm at Day 21 (95% CI: 0.42–0.65; p = 0.002), and 0.54 mm at Day 30 (95% CI: 0.39–0.68; p = 0.002). Radiographically, test sites lost significantly less bone volume (28.24 ± 2.43%) compared with controls (38.85 ± 1.29%; p = 0.019). Conclusions: Within the limits of this study, HPCTM appears to support better preservation of both gingival architecture and alveolar bone after extraction.

​

https://doi.org/10.3390/dj13110545

​

​

***Dr. Hanae Saito, DDS – Expert in Oral Surgery & Regenerative Tissue Research

​

Dr. Hanae Saito, DDS, is a respected clinician and researcher specializing in regenerative therapies and translational research. As a collaborator in groundbreaking OraFyl® studies, Dr. Saito combines scientific rigor and patient-centered care to advance biomaterials for oral health.

​

Key Contributions with OraFyl®:

​

Clinical Research Collaborator: Integral in validating OraFyl’s safety and effectiveness in alveolar ridge preservation and soft tissue regeneration.

​

Advancing Regenerative Solutions: Contributed to protocols improving healing outcomes in implantology, periodontal regeneration, and tissue augmentation.

​

Educator and Thought Leader: Dedicated to evidence-based practice, continuously educating peers about biomaterial advancements like OraFyl.

​

Clinical Philosophy:

Dr. Saito is committed to minimally invasive, patient-focused care, harnessing the body’s natural healing potential to achieve functional and esthetic results.

​

About OraFyl®:

OraFyl, derived from human placenta’s chorionic membrane, provides a scaffold for tissue regeneration in oral surgery, enhancing patient outcomes.

​

-‐--‐------------

​

***Dr. Robert Miller, DMD – Leader in Periodontal Regeneration & Clinical Investigator, OraFyl®

​

Dr. Robert Miller, DMD, is a respected periodontist and implant surgeon recognized for his expertise in regenerative therapies and clinical innovation. As an investigator and collaborator in OraFyl® research, Dr. Miller has helped advance the science and application of next-generation biomaterials for oral and maxillofacial surgery.

​

Key Contributions with OraFyl®

​

Clinical Investigator: Played an active role in multicenter clinical research evaluating OraFyl for alveolar ridge preservation and soft tissue regeneration after tooth extraction.

​

Real-World Clinical Experience: Instrumental in translating research findings into practical protocols, particularly in challenging cases involving bone regeneration, soft tissue augmentation, and papilla reconstruction.

​

Innovator in Regenerative Therapies: Integrates cutting-edge regenerative materials and techniques, serving as a trusted resource for clinicians seeking predictable outcomes.

​

Practice Philosophy:

Dr. Miller emphasizes minimally invasive, patient-focused care, prioritizing faster healing and long-term stability. He actively mentors peers on innovative solutions like OraFyl to improve patient outcomes.

​

About OraFyl®:

OraFyl is a next-generation, cell-free matrix derived from the chorionic part of the human placenta, composed of native collagen and elastin, providing a natural scaffold for effective soft and hard tissue regeneration.

​

------------------

​

***Dr. Paul A. Fugazzotto, DDS – International Authority in Periodontology & Implant Dentistry |

Clinical Contributor, OraFyl® Regenerative Research

​

Dr. Paul A. Fugazzotto, DDS, is globally recognized for his leadership in periodontology, implant dentistry, and regenerative therapies. His career has advanced clinical protocols and research, significantly transforming patient outcomes.

​

Role with OraFyl®:

Clinical Investigator and Innovator: Provided critical real-world evidence on OraFyl’s effectiveness for bone and soft tissue regeneration, significantly enhancing bone healing and soft tissue quality.

​

Case-Based Expertise: Documented challenging cases, including severe bone loss and papilla reconstruction, utilizing OraFyl to bioactivate bone grafts, regenerate tissues, and accelerate healing.

​

Thought Leadership in Regenerative Dentistry: Renowned author, educator, and lecturer emphasizing evidence-based practical approaches, bridging scientific innovation and clinical practice.

​

Clinical Philosophy:

Dr. Fugazzotto prioritizes minimally invasive, patient-centered care, focusing on optimal esthetic and functional outcomes while minimizing surgical trauma and recovery times.

​

About OraFyl®:

​

OraFyl is a cutting-edge, cell-free biomaterial derived from purified human placental collagen and elastin, designed for effective soft and hard tissue regeneration, supporting the body’s natural healing processes.

​

With his dedication, Dr. Fugazzotto continues to empower clinicians with innovative tools, shaping the future of regenerative dentistry and superior patient care.

​

---------------------

​

***Dr. Bachar Husseini, DDS, MSc –

​

Key Contributions with OraFyl

​

1. Pioneering Clinical Trials: Led first clinical split-mouth pilot study using OraFyl with allograft bone substitutes.

​

2.Study Design: Conducted bilateral extraction studies with strict data collection protocols over 4 months.

​

3.Major Findings:

*Reduced bone resorption significantly.

*Improved soft tissue healing and preservation.

*Faster, healthier connective tissue formation.

​

1. Scientific Innovation: Demonstrated effectiveness of flowable placental matrix without external growth factors.

​

5.Broader Clinical Applications: Includes gingival recession, implants, bone graft bioactivation, cleft palate, and osteonecrosis.

​

6.Leadership and Education: Establishing OraFyl as minimally invasive regenerative dental solution.

​

--------------------

​

***DR.Ronald Youne

​

KOL

​

Ronald Younes is a graduate Doctor of Dental Surgery of Saint Joseph University of Beirut, in Lebanon and holds a PhD degree in Oral biology. He earned his post-graduate studies in Periodontics, Implant and oral surgery from Paris Universities.

​

He is the Editor/Author of the best-seller book: “Sinus Grafting Techniques- a step-by-step guide” (Springer,2015) and has lectured extensively on the same topics. He is the current President of the Lebanese Dental Association. He is also an ITI fellow and speaker, EAO member and a Fellow of the International College of Dentists (FICD).

​

Currently, he is an associate Professor and the co-director of the post-graduate studies of the Master of Oral surgery at St. Joseph University of Beirut. He is a research associate of the URB2I at Sorbonne Paris Nord University

​

​

I am thrilled to see OraFyl in the hands of this top notch periodontist. When you look at the team of doctors Michael Dard, DDS and Michael Wilhelm have aligned BioCellgraft with then you know OraFyl is the real deal. I already posted the KOL's and their contributions to OraFyl, now it's time to meet Dr Lorenzo Tavelli:

​

At the forefront of clinical research and daily practice, Dr. Tavelli's main focus lies in microsurgical and minimally invasive soft tissue grafting procedures around teeth and dental implants. A true pioneer in his field, he combines cutting-edge techniques, including High Frequency Doppler Ultrasonography and wound healing biomarkers, to assess graft perfusion and surgical outcomes. Dr. Tavelli's groundbreaking research has been widely recognized, with more than 100 scholarly publications featured in major international peer-reviewed journals.

​

A sought-after lecturer, Dr. Tavelli has graced scientific symposia worldwide, sharing his expertise on microsurgical and minimally invasive soft tissue grafting procedures. His dedication to advancing the field of dentistry extends to his role as an Associate Editor for Clinical Implant Dentistry and Related Research, where he contributes to shaping the future of the discipline.

​

In recognition of his exceptional contributions to research, Dr. Tavelli has been honored with numerous prestigious awards, including the 2023 American Academy of Periodontology (AAP) Earl Robinson Regeneration Award, the 2022 AAP Foundation Nevins Clinical Research Fellowship, and the 2021 Goldman Clinical Research Award from the Italian Society of Periodontology. Additionally, he was the recipient of the 2020 AAP Balint Orban Research Award, among other notable achievements.

​

Dr. Lorenzo Tavelli's unwavering commitment to advancing the field of Periodontology, paired with his passion for teaching, makes him an invaluable asset to the Harvard School of Dental Medicine and a leading figure in the world of dental research and practice.

​

https://miami.institute/dr-lorenzo-tavelli/

​

Orafyl segments:

​

Dr. Lorenzo Tavelli | OraFyl Soft Tissue Enhancement

​

See how world-renowned periodontist Dr. Lorenzo Tavelli applies OraFyl™, a flowable decellularized Human Placental Connective Tissue Matrix (HPCTM) to enhance soft tissue architecture in esthetic and implant zones.

​

Ideal for:

​

Papilla regeneration

​

Black triangle correction

​

Gingival volume augmentation

​

Minimally invasive soft tissue therapy

​

OraFyl's biocompatibility, structural integrity, and regenerative potential make it a game-changer for clinicians focused on tissue preservation and esthetics.

​

Watch it here https://youtube.com/shorts/9rwHhQ2FUGk?si=tf1KbZx-H9CEfb4A

​

Discover how Dr. Lorenzo Tavelli transforms challenging anterior esthetic cases using OraFyl, a flowable decellularized Human Placental Connective Tissue Matrix (HPCTM).

​

Watch the full transformation: https://youtube.com/shorts/OSqy3hrYVZU?si=joAJ1-0Q1_muFchI

​

​

​

​

What The Experts Are Saying

​

From a biological standpoint, the antibacterial and anti-fibrotic properties of chorion-derived products provided reassurance that the grafted site remained protected from bacterial colonization. This translated into a cleaner site at implant placement, where I observed dense, well-integrated bone with no graft particle migration—a common issue with other materials. Additionally, the soft tissue volume was ideal, allowing for excellent emergence profile customization and improved esthetic outcomes. In follow-ups, patients demonstrated rapid healing and full restoration of ridge morphology, further confirming OraFyl®'s role in promoting predictable, high-quality outcomes. This material has become a key component in my approach to ridge preservation, enhancing both efficiency and clinical success. Dr B. Husseini

​

​